Bio-Rad Laboratories Statistics
Total Valuation
BIO has a market cap or net worth of $7.22 billion. The enterprise value is $7.17 billion.
| Market Cap | 7.22B |
| Enterprise Value | 7.17B |
Important Dates
The last earnings date was Thursday, February 12, 2026, after market close.
| Earnings Date | Feb 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BIO has 26.99 million shares outstanding. The number of shares has decreased by -3.31% in one year.
| Current Share Class | 21.92M |
| Shares Outstanding | 26.99M |
| Shares Change (YoY) | -3.31% |
| Shares Change (QoQ) | +0.33% |
| Owned by Insiders (%) | 6.48% |
| Owned by Institutions (%) | 72.67% |
| Float | 21.13M |
Valuation Ratios
The trailing PE ratio is 9.74 and the forward PE ratio is 26.41.
| PE Ratio | 9.74 |
| Forward PE | 26.41 |
| PS Ratio | 2.83 |
| Forward PS | 2.75 |
| PB Ratio | 0.98 |
| P/TBV Ratio | 1.09 |
| P/FCF Ratio | 19.55 |
| P/OCF Ratio | 13.76 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.61, with an EV/FCF ratio of 19.13.
| EV / Earnings | 9.43 |
| EV / Sales | 2.77 |
| EV / EBITDA | 16.61 |
| EV / EBIT | 26.93 |
| EV / FCF | 19.13 |
Financial Position
The company has a current ratio of 5.62, with a Debt / Equity ratio of 0.19.
| Current Ratio | 5.62 |
| Quick Ratio | 3.89 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 2.78 |
| Debt / FCF | 3.70 |
| Interest Coverage | 5.43 |
Financial Efficiency
Return on equity (ROE) is 10.84% and return on invested capital (ROIC) is 2.90%.
| Return on Equity (ROE) | 10.84% |
| Return on Assets (ROA) | 1.67% |
| Return on Invested Capital (ROIC) | 2.90% |
| Return on Capital Employed (ROCE) | 2.65% |
| Weighted Average Cost of Capital (WACC) | 9.47% |
| Revenue Per Employee | $346,738 |
| Profits Per Employee | $102,000 |
| Employee Count | 7,450 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 1.65 |
Taxes
In the past 12 months, BIO has paid $235.60 million in taxes.
| Income Tax | 235.60M |
| Effective Tax Rate | 23.67% |
Stock Price Statistics
The stock price has decreased by -4.21% in the last 52 weeks. The beta is 1.18, so BIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.18 |
| 52-Week Price Change | -4.21% |
| 50-Day Moving Average | 301.82 |
| 200-Day Moving Average | 282.81 |
| Relative Strength Index (RSI) | 34.42 |
| Average Volume (20 Days) | 291,271 |
Short Selling Information
The latest short interest is 819,074, so 3.03% of the outstanding shares have been sold short.
| Short Interest | 819,074 |
| Short Previous Month | 864,116 |
| Short % of Shares Out | 3.03% |
| Short % of Float | 3.88% |
| Short Ratio (days to cover) | 3.69 |
Income Statement
In the last 12 months, BIO had revenue of $2.58 billion and earned $759.90 million in profits. Earnings per share was $27.85.
| Revenue | 2.58B |
| Gross Profit | 1.34B |
| Operating Income | 266.10M |
| Pretax Income | 995.50M |
| Net Income | 759.90M |
| EBITDA | 431.50M |
| EBIT | 266.10M |
| Earnings Per Share (EPS) | $27.85 |
Balance Sheet
The company has $1.54 billion in cash and $1.38 billion in debt, with a net cash position of $155.90 million or $5.78 per share.
| Cash & Cash Equivalents | 1.54B |
| Total Debt | 1.38B |
| Net Cash | 155.90M |
| Net Cash Per Share | $5.78 |
| Equity (Book Value) | 7.45B |
| Book Value Per Share | 276.16 |
| Working Capital | 2.39B |
Cash Flow
In the last 12 months, operating cash flow was $532.20 million and capital expenditures -$157.60 million, giving a free cash flow of $374.60 million.
| Operating Cash Flow | 532.20M |
| Capital Expenditures | -157.60M |
| Free Cash Flow | 374.60M |
| FCF Per Share | $13.88 |
Margins
Gross margin is 52.01%, with operating and profit margins of 10.30% and 29.42%.
| Gross Margin | 52.01% |
| Operating Margin | 10.30% |
| Pretax Margin | 38.54% |
| Profit Margin | 29.42% |
| EBITDA Margin | 16.70% |
| EBIT Margin | 10.30% |
| FCF Margin | 14.50% |
Dividends & Yields
BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.31% |
| Shareholder Yield | 3.31% |
| Earnings Yield | 10.38% |
| FCF Yield | 5.12% |
Analyst Forecast
The average price target for BIO is $358.50, which is 33.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $358.50 |
| Price Target Difference | 33.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 1.78% |
| EPS Growth Forecast (5Y) | -24.58% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 8, 2002. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 8, 2002 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
BIO has an Altman Z-Score of 3.17 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.17 |
| Piotroski F-Score | 4 |